Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 612-621

  Fabbri, Chiara ^a   Drago, Antonio ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressant; Glutamate; Major depression; Pathway analysis; Pharmacogenetics

Indexed keywords

CITALOPRAM; GLUTAMATE RECEPTOR;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; GENE; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; MODULATION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL;

ADULT; AFRICAN AMERICANS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DATABASES, GENETIC; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GLUTAMIC ACID; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878846167     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.07.006     Document Type: Article

References (37)

1. Ambrosini A., Bresciani L., Fracchia S., et al. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-d-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol. Pharmacol. 1995, 47:1057-1064.
2. Anderson C.A., Pettersson F.H., Clarke G.M., et al. Data quality control in genetic case-control association studies. Nat. Protoc. 2010, 5:1564-1573.
3. Ban T.A. Pharmacotherapy of depression: a historical analysis. J. Neural Transm. 2001, 108:707-716.
4. Cassidy F., Weiner R.D., Cooper T.B., et al. Combined catecholamine and indoleamine depletion following response to ECT. Br. J. Psychiatry 2010, 196:493-494.
5. Drago A., Crisafulli C., Sidoti A., et al. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog. Neurobiol. 2011, 94:418-460.
6. Garriock H.A., Kraft J.B., Shyn S.I., et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 2010, 67:133-138.
7. Horstmann S., Lucae S., Menke A., et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
8. Howland R.H., Rush A.J., Wisniewski S.R., et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009, 99:248-260.
9. Laje G., Paddock S., Manji H., et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 2007, 164:1530-1538.
10. Lee Y.I., Koo Y.J., Cho C.H., et al. Repeated electroconvulsive shock treatment increases the expression of A kinase anchoring proteins in the rat hippocampus. Neurosci. Lett. 2004, 355:213-216.
11. Lin C.H., Lane H.Y., Chen C.C., et al. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J. Clin. Psychopharmacol. 2011, 31:187-193.
12. McMahon F.J., Buervenich S., Charney D., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78:804-814.
13. Murrough J.W. Ketamine as a novel antidepressant: from synapse to behavior. Clin. Pharmacol. Ther. 2012, 91:303-309.
14. *D cohort. Am. J. Psychiatry 2007, 164:1181-1188.
15. Perlis R.H., Fijal B., Dharia S., et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol. Psychiatry 2010, 67:1110-1113.
16. Perlis R.H., Laje G., Smoller J.W., et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009, 34:1819-1828.
17. Pitychoutis P.M., Zisaki A., Dalla C., et al. Pharmacogenetic insights into depression and antidepressant response: does sex matter?. Curr. Pharm. Des. 2010, 16:2214-2223.
18. Porcelli S., Drago A., Fabbri C., et al. Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci. 2011, 36:87-113.
19. Posternak M.A., Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br. J. Psychiatry 2007, 190:287-292.
20. Purcell S., Neale B., Todd-Brown K., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
21. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 2007, 12:331-359.
22. Sanderson J.L., Dell'Acqua M.L. AKAP signaling complexes in regulation of excitatory synaptic plasticity. Neuroscientist 2011, 17:321-336.
23. Saus E., Brunet A., Armengol L., et al. Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients. J. Psychiatr Res. 2010, 44:971-978.
24. Serretti A., Franchini L., Gasperini M., et al. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr. Scand. 1998, 98:443-450.
25. Shigemoto R., Kinoshita A., Wada E., et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 1997, 17:7503-7522.
26. Shyn S.I., Shi J., Kraft J.B., et al. Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol. Psychiatry 2011, 16:202-215.
27. Skol A.D., Scott L.J., Abecasis G.R., et al. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 2006, 38:209-213.
28. Slattery D.A., Hudson A.L., Nutt D.J. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 2004, 18:1-21.
29. Smith G.S., Workman C.I., Kramer E., et al. The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. Am. J. Geriatr. Psychiatry 2011, 19:53-63.
30. Tardito D., Musazzi L., Tiraboschi E., et al. Early induction of CREB activation and CREB-regulating signalling by antidepressants. Int. J. Neuropsychopharmacol. 2009, 12:1367-1381.
31. Taylor M.J., Freemantle N., Geddes J.R., et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry 2006, 63:1217-1223.
32. Trivedi M.H., Rush A.J., Ibrahim H.M., et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 2004, 34:73-82.
33. *D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
34. *D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
35. Wieronska J.M., Klak K., Palucha A., et al. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res. 2007, 1184:88-95.
36. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
37. Zhou R., Yuan P., Wang Y., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009, 34:1395-1405.